SARS-CoV2 Genome Sequencing in India
Clevergene signs an MoU with CSIR-CFRI (Central Food Technological Study Institute) for sequencing SARS-CoV2 Genome, as part of numerous efforts towards reducing COVID-19.
Sequencing the virus’ genome will assist track its genome alterations and its growth in the area, driving running studies into an effective vaccine and aid examine the efficiency of the specific vaccine against COVID-19.
It is anticipated that the project would offer insights right into the virus’s genome modifications, epidemiology, evolution, as well as offer a comprehension of the temporal and spatial details on infection mechanism of the SARS-CoV-2.
The joint research with CFTRI and Bengaluru-centered genomics studies establishment Clevergene belongs to genome sequencing effort conducted all around India that entails several establishments collecting samples of the coronavirus from their corresponding regions as well as CFTRI providing samples from the Mysuru part.
It will certainly be a joint initiative with the company. They will target samples of SARS-CoV-2 from the Mysuru area and their initiatives will be to uncover whether there is any kind of variation within the virus that is affecting individuals in the region and likewise locate the trajectory and source of the novel virus, claimed Dr. Prakash M Halami, the primary researcher
and nodal officer, CFTRI.He mentioned that if the study is paired with research on antibody reaction, it would certainly aid evaluate the efficacy of vaccine contenders. The research study would also probably assist comprehend why the infection of the virus decreased around mid-October in spite of a festive season when individuals gathered in huge numbers sans preventative measures, the adept stated.
Under the MoU, the production of novel vaccines and diagnostics for COVID-19 are proposed, according to the organization. CSIR-CFTRI has built a COVID-19 Examination Centre in Mysuru and approximately 1,000 examples are examined daily.
CFTRI is also studying the creation of unique dipstick and aptamer-based diagnostic methods in cooperation with private firms. Clevergene is a technology firm providing genomics services for agreement research study and hereditary diagnostics, reported in a release.
The MoU was exchanged between B. Manohar, Principal Scientist as well as Adviser, and Tony Jose, Co-Founder & CEO, Clevergene.
SARS-CoV2 Genome Sequencing
Author : Geema George
